» Articles » PMID: 15709027

Quasispecies Heterogeneity Within the E1/E2 Region As a Pretreatment Variable During Pegylated Interferon Therapy of Chronic Hepatitis C Virus Infection

Overview
Journal J Virol
Date 2005 Feb 15
PMID 15709027
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

A series of 29 patients undergoing treatment for chronic hepatitis C virus (HCV) genotype 1 infection with pegylated alpha-2a interferon plus ribavirin were studied for patterns of response to antiviral therapy and viral quasispecies evolution. All patients were treatment naive and had chronic inflammation and fibrosis on biopsy. As part of an analysis of pretreatment variables that might affect the outcome of treatment, genetic heterogeneity within the viral E1-E2 glycoprotein region (nucleotides 851 to 2280) was assessed by sequencing 10 to 15 quasispecies clones per patient from serum-derived PCR products. Genetic parameters were examined with respect to response to therapy based on serum viral RNA loads at 12 weeks (early viral response) and at 24 weeks posttreatment (sustained viral response). Nucleotide and amino acid quasispecies complexities of the hypervariable region 1 (HVR-1) were less in the responder group in comparison to the nonresponder group at 12 weeks, and genetic diversity was also less both within and outside of the HVR-1, with the difference being most pronounced for the non-HVR-1 region of E2. However, these genetic parameters did not distinguish responders from nonresponders for sustained viral responses. Follow-up studies of genetic heterogeneity based on the HVR-1 in selected responders and nonresponders while on therapy revealed greater evolutionary drift in the responder subgroup. The pretreatment population sequences for the NS5A interferon sensitivity determinant region were also analyzed for all patients, but no correlations were found between treatment response and any distinct genetic markers. These findings support previous studies indicating a high level of genetic heterogeneity among chronically infected HCV patients. One interpretation of these data is that early viral responses are governed to some extent by viral factors, whereas sustained responses may be more influenced by host factors, in addition to effects of viral complexity and diversity.

Citing Articles

The dynamic changes of HBV quasispecies diversity in infancy after immunoprophylaxis failure: a prospective cohort study.

Li Y, Xiao Y, Li L, Song Y, Zhai X, Liu J Virol J. 2021; 18(1):236.

PMID: 34844612 PMC: 8628401. DOI: 10.1186/s12985-021-01707-9.


Genome-wide capture sequencing to detect hepatitis C virus at the end of antiviral therapy.

Peng P, Xu Y, Fried M, Di Bisceglie A, Fan X BMC Infect Dis. 2020; 20(1):632.

PMID: 32847527 PMC: 7448998. DOI: 10.1186/s12879-020-05355-2.


Hepatitis C virus: Promising discoveries and new treatments.

Bastos J, Padilla M, Caserta L, Miotto N, Vigani A, Arns C World J Gastroenterol. 2016; 22(28):6393-401.

PMID: 27605875 PMC: 4968121. DOI: 10.3748/wjg.v22.i28.6393.


Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study.

Zhang X, Li M, Cao Y, Zhang R, Zhang Y, Li F Medicine (Baltimore). 2016; 95(4):e2614.

PMID: 26825915 PMC: 5291585. DOI: 10.1097/MD.0000000000002614.


Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice.

Chen R, Kobewka M, Addison W, LaChance G, Tyrrell D PLoS One. 2016; 11(1):e0147007.

PMID: 26765841 PMC: 4713165. DOI: 10.1371/journal.pone.0147007.


References
1.
Ni J, Hembrador E, Di Bisceglie A, Jacobson I, Talal A, Butera D . Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients. J Immunol. 2003; 170(6):3429-39. DOI: 10.4049/jimmunol.170.6.3429. View

2.
Pawlotsky J, Pellerin M, Bouvier M, Roudot-Thoraval F, Germanidis G, Bastie A . Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. J Med Virol. 1998; 54(4):256-64. View

3.
Squadrito G, Leone F, Sartori M, Nalpas B, Berthelot P, Raimondo G . Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology. 1997; 113(2):567-72. DOI: 10.1053/gast.1997.v113.pm9247477. View

4.
Thelu M, Baud M, Leroy V, Seigneurin J, Zarski J . Dynamics of viral quasispecies during interferon therapy in non responder chronic hepatitis C patients. J Clin Virol. 2001; 22(1):125-31. DOI: 10.1016/s1386-6532(01)00174-3. View

5.
Hadziyannis S, Sette Jr H, Morgan T, Balan V, Diago M, Marcellin P . Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5):346-55. DOI: 10.7326/0003-4819-140-5-200403020-00010. View